- Home
- OS vs BPMC Comparison
OS vs BPMC Comparison
Compare OS & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OS
- BPMC
- Stock Information
- Founded
- OS 2012
- BPMC 2008
- Country
- OS United States
- BPMC United States
- Employees
- OS N/A
- BPMC N/A
- Industry
- OS
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- OS
- BPMC Health Care
- Exchange
- OS NYSE
- BPMC Nasdaq
- Market Cap
- OS 6.7B
- BPMC 5.8B
- IPO Year
- OS 2024
- BPMC 2015
- Fundamental
- Price
- OS $28.06
- BPMC $101.35
- Analyst Decision
- OS Strong Buy
- BPMC Buy
- Analyst Count
- OS 22
- BPMC 18
- Target Price
- OS $32.15
- BPMC $125.88
- AVG Volume (30 Days)
- OS 1.5M
- BPMC 789.4K
- Earning Date
- OS 05-08-2025
- BPMC 05-01-2025
- Dividend Yield
- OS N/A
- BPMC N/A
- EPS Growth
- OS N/A
- BPMC N/A
- EPS
- OS N/A
- BPMC N/A
- Revenue
- OS $515,424,999.00
- BPMC $562,121,000.00
- Revenue This Year
- OS $23.36
- BPMC $44.49
- Revenue Next Year
- OS $19.74
- BPMC $33.04
- P/E Ratio
- OS N/A
- BPMC N/A
- Revenue Growth
- OS 26.83
- BPMC 99.19
- 52 Week Low
- OS $16.69
- BPMC $73.04
- 52 Week High
- OS $35.39
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- OS N/A
- BPMC 56.34
- Support Level
- OS N/A
- BPMC $94.38
- Resistance Level
- OS N/A
- BPMC $102.52
- Average True Range (ATR)
- OS 0.00
- BPMC 3.77
- MACD
- OS 0.00
- BPMC -0.38
- Stochastic Oscillator
- OS 0.00
- BPMC 79.29
About OS ONESTREAM INC
OneStream Inc is an AI-enabled and extensible software platform that unifies core financial functions and broader operational data and processes within a single platform. The Digital Finance Cloud of the company provides a comprehensive, dynamic, and predictive view of the entire enterprise, providing corporate leaders the control, visibility, and agility required to proactively adjust business and day-to-day execution.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.